Second-Line mFOLFOX3 Has Modest Effect in Previously Treated Biliary Tract Cancer
Second-line mFOLFOX3 has modest effect in unresectable and/or metastatic biliary tract cancer.
According to a new study published in the journal Cancer Chemotherapy and Pharmacology, researchers have found that second-line mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) has modest effect and tolerable toxicity in patients with unresectable and/or metastatic biliary tract cancer who have been previously treated with gemcitabine-based chemotherapy.
For the phase 2 study, researchers enrolled 30 patients between March 2010 and June 2012 to receive oxaliplatin 85mg/m2 on day 1 and leucovorin 30mg on days 1 and 2 followed by 5-fluorouracil 1,500mg/m2 on days 1 and 2 every 2 weeks.
Results showed that of the 28 evaluable patients, one achieved a complete response and one achieved a partial response, equating to an overall response rate of 7.1% (95% CI: 0.9 - 23.5%). The median overall survival and progression free survival was 4.4 and 1.6 months, respectively.
RELATED: Tumor-Specific Differences, Genomic Alterations of Biliary Tract Cancers Identified
The most common non-hematologic adverse event was neuropathy, while the most common severe toxicity was hyperbilirubinemia. The most common severe hematologic toxicities were neutropenia and thrombocytopenia. One patient died as a result of neutropenic infection.